<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Blood</journal-id>
<journal-id journal-id-type="iso-abbrev">Blood</journal-id>
<journal-id journal-id-type="hwp">bloodjournal</journal-id>
<journal-id journal-id-type="pmc">blood</journal-id>
<journal-id journal-id-type="publisher-id">Blood</journal-id>
<journal-title-group>
<journal-title>Blood</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-4971</issn>
<issn pub-type="epub">1528-0020</issn>
<publisher>
<publisher-name>American Society of Hematology</publisher-name>
<publisher-loc>Washington, DC</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29113963</article-id>
<article-id pub-id-type="pmc">5774208</article-id>
<article-id pub-id-type="publisher-id">2017/789669</article-id>
<article-id pub-id-type="doi">10.1182/blood-2017-06-789669</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>33</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Myeloid Neoplasia</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Hui</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="author-notes" rid="fn1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kurtenbach</surname>
<given-names>Stefan</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff3">3</xref>
<xref ref-type="author-notes" rid="fn1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="author-notes" rid="fn1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lohse</surname>
<given-names>Ines</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Durante</surname>
<given-names>Michael A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Jianping</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Zhaomin</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Ali</surname>
<given-names>Hassan</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Lingxiao</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Zizhen</given-names>
</name>
<xref ref-type="aff" rid="aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Field</surname>
<given-names>Matthew G.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-3394-6922</contrib-id>
<name>
<surname>Zhang</surname>
<given-names>Peng</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Shi</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>Shohei</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Zhuo</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Yuan</given-names>
</name>
<xref ref-type="aff" rid="aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nimer</surname>
<given-names>Stephen D.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harbour</surname>
<given-names>J. William</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wahlestedt</surname>
<given-names>Claes</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Mingjiang</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Feng-Chun</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<aff id="aff1"><label>1</label>Sylvester Comprehensive Cancer Center, </aff>
<aff id="aff2"><label>2</label>Department of Biochemistry and Molecular Biology, </aff>
<aff id="aff3"><label>3</label>Bascom Palmer Eye Institute, </aff>
<aff id="aff4"><label>4</label>Center for Therapeutic Innovation and Department of Psychiatry and Behavioral Sciences, </aff>
<aff id="aff5"><label>5</label>Department of Neurological Surgery, The Miami Project to Cure Paralysis, Peggy and Harold Katz Family Drug Discovery Center, and </aff>
<aff id="aff6"><label>6</label>Department of Internal Medicine, University of Miami Miller School of Medicine, Miami, FL; and </aff>
<aff id="aff7"><label>7</label>State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital and Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China</aff>
</contrib-group>
<author-notes>
<fn fn-type="equal" id="fn1">
<label>*</label>
<p>H.Y., S.K., and Y.G. contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>18</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epreprint">
<day>07</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>18</day>
<month>1</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>131</volume>
<issue>3</issue>
<fpage>328</fpage>
<lpage>341</lpage>
<history>
<date date-type="received">
<day>08</day>
<month>6</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>10</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 by The American Society of Hematology</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<self-uri xlink:href="blood789669.pdf" xlink:title="pdf"></self-uri>
<related-article ext-link-type="doi" id="d35e338" related-article-type="article-reference" xlink:href="10.1182/blood-2017-12-816595">Kitamura</related-article>
<abstract abstract-type="teaser">
<p><bold>Publisher's Note:</bold> There is a <related-article ext-link-type="doi" id="d35e345" related-article-type="article-reference" xlink:href="10.1182/blood-2017-12-816595"><italic>Blood</italic> Commentary</related-article> on this article in this issue.</p>
</abstract>
<abstract abstract-type="executive-summary">
<title>Key Points</title>
<p>
<list list-type="bullet">
<list-item>
<p>Transgenic expression of ASXL1<sup>aa1-587</sup> truncating protein in the hematopoietic system leads to diverse myeloid malignancies in mice.</p>
</list-item>
<list-item>
<p>ASXL1<sup>aa1-587</sup> gains an interaction with BRD4 and <italic>Asxl1</italic><sup><italic>Y588X</italic></sup>Tg hematopoietic stem/progenitor cells are hypersensitive to BET bromodomain inhibitors.</p>
</list-item>
</list>
</p>
</abstract>
<abstract>
<p>Additional Sex Combs-Like 1 (<italic>ASXL1</italic>) is mutated at a high frequency in all forms of myeloid malignancies associated with poor prognosis. We generated a <italic>Vav1</italic> promoter-driven <italic>Flag-Asxl1</italic><sup><italic>Y588X</italic></sup> transgenic mouse model, <italic>Asxl1</italic><sup><italic>Y588X</italic></sup>Tg, to express a truncated FLAG-ASXL1<sup>aa1-587</sup> protein in the hematopoietic system. The <italic>Asxl1</italic><sup><italic>Y588X</italic></sup>Tg mice had an enlarged hematopoietic stem cell (HSC) pool, shortened survival, and predisposition to a spectrum of myeloid malignancies, thereby recapitulating the characteristics of myeloid malignancy patients with <italic>ASXL1</italic> mutations. ATAC- and RNA-sequencing analyses revealed that the ASXL1<sup>aa1-587</sup> truncating protein expression results in more open chromatin in cKit<sup>+</sup> cells compared with wild-type cells, accompanied by dysregulated expression of genes critical for HSC self-renewal and differentiation. Liquid chromatography–tandem mass spectrometry and coimmunoprecipitation experiments showed that ASXL1<sup>aa1-587</sup> acquired an interaction with BRD4. An epigenetic drug screening demonstrated a hypersensitivity of <italic>Asxl1</italic><sup><italic>Y588X</italic></sup>Tg bone marrow cells to BET bromodomain inhibitors. This study demonstrates that ASXL1<sup>aa1-587</sup> plays a gain-of-function role in promoting myeloid malignancies. Our model provides a powerful platform to test therapeutic approaches of targeting the <italic>ASXL1</italic> truncation mutations in myeloid malignancies.</p>
</abstract>
<funding-group>
<award-group id="sp1">
<funding-source>
<institution-wrap>
<institution>National Institutes of Health</institution>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="14"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>